CTSO: A 10% price move on Friday will have investors interested this coming week.
News of secondary endpoints for the European CytoSorb trial will be key in determining the market potential of the CytoSorb, once commercialized, and the prospects of the company landing a deep-pocketed partner to help out with the launch also offers a short term catalyst.
Friday's move was not accompanied by high volume, but it's only a matter of time before the riddle of secondaries is solved.
If the next announcements from the company are positive follow-ups to the approval news, then the post-approval highs should easily be broken as a commercial launch of CytoSorb draws nearer.
Disclosure: Long CTSO.
GNBT: With a vote on a reverse split looming for June 8th, keep an eye on shares of Generex.
The company has pulled out all the stops to compel shareholders to vote 'Yes' for the split, but as I described HERE, the case for an r/s should sell itself, and Generex almost looks desperate in its attempt to persuade the shareholders to tote the company line.
A higher share price, according to the company, and a listing on a 'big board' would attract more institutional money, which would benefit shareholders as well as Generex.
It's my opinion, however, that a good story sells itself, and the long-time silence on Oral-lyn has investors believing that the story might not be so good after all.
Still an attractive pick, but it might be a better one on the other side of the r/s, if it's voted for.
This week will be a telling one for Generex.
Disclosure: No position.
APRI: June 8th is another solid date for the biotech investor, as the CEO of Apricus Biosciences is set to present Jefferies 2011 Global Healthcare Conference in New York City on that date.
At the conference, CEO Bassam Damaj will discuss the commercialization plans for Vitaros, the company's topical treatment for erectile dysfunction that was approved in Canada last year.
A partnership is always a good part of commercialization, so it's possible that investors will receive an update on that front.
A presentation of a plan for Vitaros commercialization will go a lot further in keeping investors interested, in my opinion, than the movies produced by the Apricus production team recently.
Investors don't want lessons in science, they want results.
For Apricus, that means landing a partner and landing some commercialization and sales stats.
APRI, already volatile for a few months now, will be worth watching this week.
Disclosure: Long APRI.
MCET: A week will have passed since MultiCell's rather significant run, and a further fall on Monday will pretty much solidify any thoughts that this latest run is over.
It's not uncommon for MCET to experience rapid price increases before falling back to previously-traded levels, but this one has always proved worthwhile to accumulate at low levels with eyes towards trading into any spikes.
That said, there's also some long term potential that exists here, so it's always worth keeping on the radar.
Disclosure: No position.
